Nifty
Sensex
:
:
17196.70
57696.46
-204.95 (-1.18%)
-764.83 (-1.31%)

Pharmaceuticals & Drugs - Global

Rating :
37/99

BSE: 530549 | NSE: SHILPAMED

561.15
03-Dec-2021
  • Open
  • High
  • Low
  • Previous Close
  •  569.30
  •  574.10
  •  554.50
  •  562.50
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  162622
  •  913.16
  •  670.40
  •  311.60

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 4,867.42
  • 132.13
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 5,588.40
  • 0.20%
  • 2.73

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 53.25%
  • 10.15%
  • 19.50%
  • FII
  • DII
  • Others
  • 12.27%
  • 2.29%
  • 2.54%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 10.97
  • 2.95
  • 7.11

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 10.89
  • 1.22
  • 2.20

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 13.75
  • 5.63
  • 7.52

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 30.59
  • 27.40
  • 24.01

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.14
  • 3.41
  • 2.56

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 21.54
  • 20.93
  • 18.23

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 21
Sep 20
Var%
Jun 21
Jun 20
Var%
Mar 21
Mar 20
Var%
Dec 20
Dec 19
Var%
Net Sales
295.27
278.94
5.85%
237.36
222.87
6.50%
208.03
219.99
-5.44%
191.25
236.85
-19.25%
Expenses
242.11
210.25
15.15%
205.48
157.11
30.79%
181.82
174.40
4.25%
170.28
163.11
4.40%
EBITDA
53.16
68.68
-22.60%
31.88
65.75
-51.51%
26.21
45.60
-42.52%
20.97
73.74
-71.56%
EBIDTM
18.00%
24.62%
13.43%
29.50%
12.60%
20.73%
10.96%
31.13%
Other Income
1.28
9.20
-86.09%
1.99
5.48
-63.69%
6.91
8.91
-22.45%
8.61
3.25
164.92%
Interest
11.58
3.95
193.16%
10.32
4.00
158.00%
9.12
1.01
802.97%
4.80
1.27
277.95%
Depreciation
19.18
12.70
51.02%
17.63
12.33
42.98%
15.23
11.55
31.86%
13.72
10.97
25.07%
PBT
32.59
61.23
-46.77%
5.92
115.74
-94.89%
8.76
41.95
-79.12%
11.05
64.76
-82.94%
Tax
11.56
15.99
-27.70%
3.56
29.14
-87.78%
0.80
7.55
-89.40%
2.92
10.53
-72.27%
PAT
21.03
45.24
-53.51%
2.36
86.60
-97.27%
7.97
34.40
-76.83%
8.14
54.24
-84.99%
PATM
7.12%
16.22%
1.00%
38.86%
3.83%
15.64%
4.25%
22.90%
EPS
2.45
5.57
-56.01%
0.19
10.59
-98.21%
0.96
4.24
-77.36%
0.94
6.75
-86.07%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Net Sales
931.91
901.13
907.91
733.39
788.83
779.16
716.43
613.80
571.38
371.32
318.18
Net Sales Growth
-2.79%
-0.75%
23.80%
-7.03%
1.24%
8.76%
16.72%
7.42%
53.88%
16.70%
 
Cost Of Goods Sold
281.12
270.73
277.73
257.03
355.87
371.81
366.19
323.16
313.26
213.95
183.22
Gross Profit
650.79
630.40
630.18
476.36
432.95
407.36
350.25
290.63
258.12
157.38
134.96
GP Margin
69.83%
69.96%
69.41%
64.95%
54.89%
52.28%
48.89%
47.35%
45.17%
42.38%
42.42%
Total Expenditure
799.69
729.42
693.39
579.39
637.60
617.55
556.44
487.38
455.40
301.63
257.08
Power & Fuel Cost
-
40.25
38.76
33.57
28.86
26.30
21.90
19.29
17.37
10.67
9.38
% Of Sales
-
4.47%
4.27%
4.58%
3.66%
3.38%
3.06%
3.14%
3.04%
2.87%
2.95%
Employee Cost
-
235.31
196.59
176.40
149.35
127.87
90.09
82.30
67.83
42.56
33.68
% Of Sales
-
26.11%
21.65%
24.05%
18.93%
16.41%
12.57%
13.41%
11.87%
11.46%
10.59%
Manufacturing Exp.
-
88.99
79.19
61.23
59.96
52.55
45.35
36.55
27.44
16.92
12.89
% Of Sales
-
9.88%
8.72%
8.35%
7.60%
6.74%
6.33%
5.95%
4.80%
4.56%
4.05%
General & Admin Exp.
-
47.67
70.26
27.20
22.50
16.95
14.11
10.64
9.53
9.51
7.87
% Of Sales
-
5.29%
7.74%
3.71%
2.85%
2.18%
1.97%
1.73%
1.67%
2.56%
2.47%
Selling & Distn. Exp.
-
20.79
10.40
6.72
6.37
4.75
7.27
5.99
7.29
4.43
3.19
% Of Sales
-
2.31%
1.15%
0.92%
0.81%
0.61%
1.01%
0.98%
1.28%
1.19%
1.00%
Miscellaneous Exp.
-
25.68
20.47
17.23
14.68
17.32
11.54
9.45
12.68
3.59
3.19
% Of Sales
-
2.85%
2.25%
2.35%
1.86%
2.22%
1.61%
1.54%
2.22%
0.97%
2.16%
EBITDA
132.22
171.71
214.52
154.00
151.23
161.61
159.99
126.42
115.98
69.69
61.10
EBITDA Margin
14.19%
19.05%
23.63%
21.00%
19.17%
20.74%
22.33%
20.60%
20.30%
18.77%
19.20%
Other Income
18.79
40.09
22.22
15.56
32.62
29.34
11.36
6.93
9.12
5.01
8.28
Interest
35.82
21.87
4.56
3.68
2.66
3.13
3.93
4.05
3.52
2.27
2.31
Depreciation
65.76
53.98
43.78
42.06
37.22
30.64
23.14
21.41
23.22
15.34
14.36
PBT
58.32
135.95
188.40
123.82
143.96
157.17
144.28
107.89
98.35
57.10
52.71
Tax
18.84
48.85
33.49
26.18
33.91
42.04
35.62
35.22
20.30
9.53
12.22
Tax Rate
32.30%
24.82%
17.78%
18.22%
23.56%
27.54%
25.11%
32.66%
21.27%
16.72%
22.91%
PAT
39.50
149.52
156.50
120.28
112.43
113.71
109.84
73.69
75.67
47.35
41.23
PAT before Minority Interest
39.76
147.94
154.91
117.52
110.05
110.59
106.24
72.62
75.15
47.47
41.11
Minority Interest
0.26
1.58
1.59
2.76
2.38
3.12
3.60
1.07
0.52
-0.12
0.12
PAT Margin
4.24%
16.59%
17.24%
16.40%
14.25%
14.59%
15.33%
12.01%
13.24%
12.75%
12.96%
PAT Growth
-82.08%
-4.46%
30.11%
6.98%
-1.13%
3.52%
49.06%
-2.62%
59.81%
14.84%
 
EPS
4.85
18.35
19.20
14.76
13.80
13.95
13.48
9.04
9.28
5.81
5.06

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Shareholder's Funds
1,478.67
1,329.36
1,197.58
1,085.03
986.90
639.26
546.94
396.45
320.42
275.98
Share Capital
8.15
8.15
8.15
8.15
8.01
7.71
7.71
7.36
4.90
4.90
Total Reserves
1,470.51
1,321.21
1,189.43
1,076.88
978.88
631.55
539.23
389.09
315.52
271.07
Non-Current Liabilities
567.90
256.94
166.62
153.48
251.26
67.23
154.15
104.53
98.51
31.13
Secured Loans
480.12
164.48
80.39
67.09
141.20
0.03
71.03
37.43
70.47
5.07
Unsecured Loans
0.35
0.53
0.70
1.03
1.30
0.00
31.30
30.05
0.00
0.00
Long Term Provisions
15.48
26.17
21.77
20.32
16.89
13.96
11.75
9.93
6.92
6.34
Current Liabilities
602.16
410.82
253.44
265.84
236.90
222.07
189.06
166.84
123.77
121.14
Trade Payables
72.15
92.55
80.72
103.74
111.86
106.48
75.50
92.98
51.26
56.72
Other Current Liabilities
275.30
142.10
81.62
59.59
28.03
36.49
49.32
38.23
23.38
20.34
Short Term Borrowings
243.40
165.27
86.58
98.12
92.41
74.10
58.47
30.27
45.07
41.24
Short Term Provisions
11.31
10.89
4.52
4.39
4.60
5.00
5.77
5.37
4.06
2.83
Total Liabilities
2,637.56
1,989.21
1,610.02
1,499.13
1,472.22
930.89
904.54
677.83
551.42
433.11
Net Block
1,110.53
650.44
558.01
534.20
491.93
393.41
316.06
294.42
180.67
166.61
Gross Block
1,421.35
986.42
853.16
793.24
704.89
582.20
476.34
448.38
300.89
271.30
Accumulated Depreciation
310.81
335.98
295.15
259.04
212.96
188.79
160.28
153.96
120.22
104.70
Non Current Assets
1,719.50
1,365.35
1,064.96
827.16
742.33
576.68
576.77
443.89
339.18
244.95
Capital Work in Progress
541.29
666.25
429.12
209.85
140.51
91.90
221.62
111.03
129.15
57.71
Non Current Investment
21.22
10.45
2.25
20.79
27.99
34.15
0.19
0.21
0.14
0.11
Long Term Loans & Adv.
43.35
32.42
48.75
37.47
77.09
51.86
38.74
38.18
28.82
20.17
Other Non Current Assets
3.11
5.78
26.84
24.86
4.80
5.36
0.16
0.06
0.40
0.34
Current Assets
918.05
623.85
545.06
671.97
729.88
354.21
327.61
233.74
211.99
187.87
Current Investments
0.00
0.00
0.00
119.54
224.62
59.63
65.35
10.14
50.28
68.02
Inventories
316.84
226.43
187.67
188.71
190.00
134.23
130.78
123.25
74.33
67.32
Sundry Debtors
222.69
246.79
203.73
220.27
170.93
125.43
81.37
67.96
41.79
40.53
Cash & Bank
123.11
44.56
94.54
73.83
100.39
11.03
18.42
9.19
16.87
2.27
Other Current Assets
255.42
76.81
45.04
26.08
43.95
23.90
31.69
23.20
28.72
9.72
Short Term Loans & Adv.
74.01
29.25
14.08
43.54
21.95
8.90
4.91
3.23
2.86
3.01
Net Current Assets
315.89
213.04
291.62
406.13
492.98
132.14
138.55
66.90
88.22
66.73
Total Assets
2,637.55
1,989.20
1,610.02
1,499.13
1,472.21
930.89
904.54
677.83
551.42
433.10

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Cash From Operating Activity
47.07
124.38
146.78
44.92
37.48
128.70
68.81
70.04
43.64
56.73
PBT
196.79
188.40
143.70
136.77
146.49
140.36
107.84
95.45
57.00
53.51
Adjustment
4.17
41.32
20.44
18.83
17.19
20.61
26.46
19.62
11.52
10.19
Changes in Working Capital
-106.29
-63.15
18.71
-69.66
-92.61
-2.70
-40.11
-23.44
-13.90
0.77
Cash after chg. in Working capital
94.67
166.57
182.85
85.94
71.08
158.27
94.19
91.62
54.62
64.46
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-47.60
-42.20
-36.07
-41.02
-33.60
-29.56
-25.38
-21.58
-10.98
-7.73
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-404.28
-289.52
-196.16
-8.76
-262.23
-109.20
-195.18
-48.93
-95.21
-152.31
Net Fixed Assets
-272.02
-4.28
-256.96
-136.75
-172.23
-92.14
-78.46
-61.02
-83.52
-79.20
Net Investments
-125.84
-4.44
141.85
95.51
-172.72
-14.09
-64.38
12.08
13.84
-73.05
Others
-6.42
-280.80
-81.05
32.48
82.72
-2.97
-52.34
0.01
-25.53
-0.06
Cash from Financing Activity
436.37
175.50
10.06
-60.91
312.70
-19.65
135.05
-28.34
66.31
10.02
Net Cash Inflow / Outflow
79.17
10.36
-39.32
-24.75
87.95
-0.15
8.68
-7.23
14.74
-85.56
Opening Cash & Equivalents
44.31
34.13
73.83
99.97
7.05
3.61
9.19
16.87
2.27
87.83
Closing Cash & Equivalent
123.34
44.31
34.36
73.83
99.97
6.43
18.42
9.19
16.87
2.27

Financial Ratios

Consolidated /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Book Value (Rs.)
181.37
163.06
146.89
133.09
123.17
82.91
70.92
107.72
43.52
74.94
ROA
6.39%
8.61%
7.56%
7.41%
9.20%
11.58%
9.18%
12.23%
9.64%
10.66%
ROE
10.54%
12.26%
10.30%
10.62%
13.60%
17.92%
15.40%
20.98%
15.93%
16.63%
ROCE
10.82%
12.41%
11.05%
11.71%
15.91%
19.90%
17.90%
20.48%
15.04%
18.02%
Fixed Asset Turnover
0.75
0.99
0.89
1.06
1.22
1.36
1.34
1.54
1.32
1.28
Receivable days
95.08
90.56
105.51
90.20
69.00
52.26
43.99
34.62
39.70
45.47
Inventory Days
110.03
83.24
93.66
87.32
75.49
66.97
74.84
62.33
68.31
62.38
Payable days
39.68
47.69
58.00
61.51
60.89
60.10
62.86
57.06
63.94
59.10
Cash Conversion Cycle
165.42
126.11
141.17
116.00
83.61
59.13
55.97
39.90
44.07
48.76
Total Debt/Equity
0.57
0.29
0.16
0.18
0.24
0.14
0.34
0.30
0.41
0.22
Interest Cover
10.00
42.34
40.09
55.10
49.69
37.07
27.63
28.09
26.13
24.13

News Update:


  • Shilpa Medicare enters Phase I Clinical Trial for its new biological entity
    1st Nov 2021, 12:28 PM

    The Company continues to strengthen its patent protection around the product to ring fence it from any potential competition

    Read More
  • Shilpa Medicare - Quarterly Results
    29th Oct 2021, 15:10 PM

    Read More
  • Shilpa Medicare ties up with Cadila Healthcare
    24th Sep 2021, 14:40 PM

    The targeted production of the ZyCoV-D vaccine from this facility will be mutually agreed upon by both parties

    Read More
  • Shilpa Medicare gets DCGI approval for ‘2-Deoxy2-Glucose’
    31st Aug 2021, 15:39 PM

    2-Deoxy-2-Glucose Oral Powder is approved for the treatment of adjunct therapy in moderate to severe COVID-19 patients

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.